A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Oncology

Background:

• Cancer remains a leading cause of mortality globally.
• Existing anticancer drugs face significant challenges including drug resistance, narrow therapeutic windows, and severe side effects.
• There is a critical need for novel anticancer agents with improved efficacy and safety profiles.

Purpose of the Study:

• To review and analyze Structure-Activity Relationship (SAR) and computational studies of 1,3,4-oxadiazole and chalcone derivatives.
• To explore the potential of these scaffolds as inhibitors of the epidermal growth factor receptor (EGFR) for cancer treatment.
• To provide insights for the design of novel, potent anticancer drug candidates.

Main Methods:

• Comprehensive literature review and analysis of published research on 1,3,4-oxadiazole and chalcone hybrids.
• Focus on Structure-Activity Relationship (SAR) studies to understand molecular modifications and their impact on activity.
• Inclusion of computational studies investigating interactions with the target receptor.

Main Results:

• 1,3,4-oxadiazole and chalcone hybrids/derivatives demonstrate significant potential as anticancer pharmacophores.
• Varied substitutions on these scaffolds are crucial for achieving potent cytotoxic and EGFR-TK inhibitory activities.
• These compounds represent a promising class of agents for developing novel cancer therapeutics.

Conclusions:

• 1,3,4-oxadiazole and chalcone hybrids are effective scaffolds for developing potent anticancer agents.
• Targeting the epidermal growth factor receptor (EGFR) with these derivatives offers a viable strategy for cancer therapy.
• This review provides valuable insights for researchers designing novel EGFR-inhibiting anticancer drug candidates.